OAM
RXST icon

Oppenheimer Asset Management’s RxSight RXST Stock Holding History

Oppenheimer Asset Management’s Portfolio RXST Stock Details RXST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-8,693
Closed -$219K – 1198
2025
Q1 		$219K Sell
8,693
-20
-0.2% -$594 ﹤0.01% 1034
2024
Q4 		$300K Buy
+8,713
New +$393K ﹤0.01% 981

Other funds holding RXST

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
NSGL
No Street GP LP San Francisco, California $1.5B AUM 34.53% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Oppenheimer Asset Management's RXST Position: Q2 2025 in Review

Oppenheimer Asset Management sold out of RxSight (RXST) in Q2 2025, closing a stake of 8,693 shares — an estimated $219K sold.

Oppenheimer Asset Management first reported a position in RXST in Q4 2024 and held it in 2 quarters. The position peaked at $300K in Q4 2024. 174 funds tracked by Wall St. Rank hold RXST as of Q2 2025.

  • Oppenheimer Asset Management reported no remaining RxSight position as of Q2 2025 after selling out during the quarter.
  • Oppenheimer Asset Management sold 8,693 RxSight shares in Q2 2025, an estimated $219K.
  • Oppenheimer Asset Management first reported a position in RxSight in Q4 2024 and held it in 2 quarters.
  • Oppenheimer Asset Management's RxSight position peaked at $300K in Q4 2024.
  • 174 funds tracked by Wall St. Rank held RxSight as of Q2 2025.

Based on Oppenheimer Asset Management's 13F filing for Q2 2025, filed 31 Jul 2025.